The aim of this study is to learn about the safety of empagliflozin in dialysis patients as a
preparation for a future large clinical trial. Empagliflozin has been approved by the Food
and Drug Administration for the treatment of either type 2 diabetes, heart failure, or
chronic kidney disease among patients not on dialysis. The use of empagliflozin has not been
studied or approved among patients on dialysis for kidney failure because empagliflozin acts
on the kidneys. However, recent experimental studies have indicated that empagliflozin may
provide direct heart benefits. Some dialysis patients have substantial residual kidney
function, which may be protected by empagliflozin.
Participants will be given empagliflozin for three (3) months on top of the standard of care
(usual medical care for your condition) and will be followed up until one (1) month after the
last dose. We will collect information about your general health, obtain blood, urine, and
imaging studies, check home blood pressure, monitor home blood sugar levels, and ask
health-related questions to assess the safety and potential benefits of empagliflozin over
four (4) months, including one month before the three (3)-month empagliflozin treatment.